Navigation Links
ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD)
Date:12/10/2009

hase II, randomized, double-blind, sham controlled trial of microplasmin intravitreal injection (125 μg) for the treatment of focal vitreomacular adhesion (separation of the vitreous from the retina) in patients with exudative (wet) AMD. The trial will enroll approximately 100 patients at up to 20 centers across five European countries. The primary endpoint of the trial is non-surgical resolution of vitreomacular adhesion, defined as the separation of the vitreous from the retina by 28 days. This will be assessed by the Central Reading Center based on optical coherence tomography (OCT) images. Additional measures of efficacy and safety will also be assessed over a one year follow-up period.

Microplasmin has the potential to transform the treatment of a number of other important back of the eye diseases as well as AMD. Microplasmin is currently being evaluated in a Phase III program of approximately 640 patients, for the non-surgical treatment of focal vitreomacular adhesion.

Dr. Patrik De Haes, CEO of ThromboGenics commenting on the announcement said, "We are very pleased to announce the start of a Phase II trial of microplasmin in such a significant condition as AMD. It is increasingly clear that vitreomacular adhesion plays a key role in AMD sufferers with a poorer prognosis. Microplasmin's potential to cleave the vitreous from the retina could therefore represent an important advance in the treatment of this patient group. The start of this trial underlines the potential broad applicability of our lead product, and is another important step as we create a profitable integrated company focused on cutting edge ophthalmic medicines."

About ThromboGenics

ThromboGenics is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of eye disease, vascular disease and cancer. The Company's lead product microplasmin is in Phase III cl
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ThromboGenics and BioInvent Complete Patient Recruitment of Phase II DVT Prophylaxis Study With Anti-Factor VIII (TB-402)
2. ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
3. ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402
4. ThromboGenics Microplasmin Phase III Program Progressing According to Schedule
5. ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
6. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
7. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
8. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
9. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
10. Boston Scientific Announces Pricing of $2 Billion of Senior Notes
11. Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 17, 2014 With advancements ... the MRI market is seeing new growth, according ... MRI scans account for the majority of market ... resolution of images, which are creating opportunities for more ... market is growing at a rate of 4%, ...
(Date:12/17/2014)... , The new Dompé website aims ... the biopharmaceutical Group,s national and international clinical research activities ... launched institutional website that is receiving accolades from all over ... chapter in the fascinating story of Drug Discovery   , ... on the world of clinical research, ranging from information for ...
(Date:12/17/2014)... -- IGI Laboratories, Inc. (NYSE MKT: IG; "IGI" or the ... $125 million aggregate principal amount of 3.75% Convertible Senior ... and sold only to qualified institutional buyers pursuant to ... amended (the "Securities Act"). The Notes bear ... payable semiannually in arrears on June 15 and December ...
Breaking Medicine Technology:Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4
... generous funding totaling more than $220,000 FHSSA and ... improve pain management among palliative care patients receiving ... Malawi. These three countries were ... care organizations, strong clinical leadership, historical success with ...
... ANGELES, Feb. 9, 2011 Design Trends: Technological Advances in Implantable Devices, ... Medical Device and Diagnostic Industry ( ... ( MPMN) , and OrthoTec ... tradeshow boasted a registration of 1,092, with an attendance of 50% during ...
Cached Medicine Technology:FHSSA and the African Palliative Care Association Launch the First-Ever Pain Management Initiative in The Gambia, Kenya, and Malawi 2Now Available: Archived Virtual Event Dedicated to Cutting-Edge Trends in Implantable Medical Devices 2Now Available: Archived Virtual Event Dedicated to Cutting-Edge Trends in Implantable Medical Devices 3
(Date:12/19/2014)... December 19, 2014 B. E. Smith, ... healthcare providers, has been retained to lead a national ... Medical Center in Estes Park, Colo. The top executive ... has recently placed more than 900 healthcare executives into ... a 25-bed, not-for-profit critical access hospital and level IV ...
(Date:12/19/2014)... On Mobile Spa, has announced they now have a ... transformed into a utopia for the Long Island community where ... Virtual Tour showcases the beauty of the Spa On Wheels ... , The Virtual Tour shows viewers each of the rooms ... Winnebago. Marla Kaplan-Pelle, Director states " It's hard to imagine ...
(Date:12/19/2014)... Slone Partners , a national recruitment ... technology, and laboratory testing industries, has promoted Leslie ... The announcement comes after a year of expansion ... in Boston and several new additions to the ... client experience," said Adam Slone, Chief Executive Officer. ...
(Date:12/19/2014)... The Hermitage Club at Haystack Mountain, ... Deerfield Valley, announced today that it has unveiled its ... , Three time Grammy Award Winner Kenny Loggins ... by a trail naming ceremony. Hermitage Club Founder, President ... Alright” the theme song for the movie soundtrack to ...
(Date:12/19/2014)... By Amy Norton ... -- Children born to moms who were exposed to high ... increased risk of developing autism, a U.S. study suggests. ... birth between 1990 and 2002, those exposed to the most ... a baby who later developed autism. And exposure during the ...
Breaking Medicine News(10 mins):Health News:Estes Park Medical Center Retains B. E. Smith to Recruit New Chief Financial Officer 2Health News:Estes Park Medical Center Retains B. E. Smith to Recruit New Chief Financial Officer 3Health News:A Virtual Tour Of Hands On Mobile Massage Spa Is Now Available 2Health News:A Virtual Tour Of Hands On Mobile Massage Spa Is Now Available 3Health News:Slone Partners Promotes Leslie Loveless to Chief Operating Officer 2Health News:The Hermitage Club Officially Names Four Ski Trails after Iconic Rock Songs by Grammy Award Winner Kenny Loggins 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 3
... UCLA team develops device giving patients freedom of movement, better ... An automated artificial kidney that can be worn on ... the insulin pump is to diabetes patients. , The automated, ... to a paper in the current issue of Clinical ...
... SUCCESS, N.Y., July 25 Anthony Shih,M.D., ... Officer and Vice President,of Strategic Planning, after ... a,national foundation committed to improving U.S. health ... on Health Care Quality,Improvement and Efficiency., ...
... therapy may be due to genetic factors , , FRIDAY, ... the long-held belief that the hepatitis C virus (HCV) ... HIV patients are treated with highly active antiretroviral therapy ... HIV-infected drug users are also infected with HCV. Intravenous ...
... Authority offers patients consumers tips and encourages them ... HARRISBURG, Pa., July 25 The Pennsylvania,Patient ... which,is a national effort to encourage patients and ... asking questions and learning,everything they can about their ...
... of Defense and Federal Agencies in, the execution ... four-day, multi-agency collaborative training event designed to ... complex incident response scenarios. Dataline is ... infrastructure for medical use during the exercise., NORFOLK, ...
... Ill., July 25 Sagent Pharmaceuticals, Inc.,a ... it,has launched amiodarone HCl injection, USP, a ... prophylaxis of frequently recurring,ventricular fibrillation and hemodynamically ... heart beat.,Sagent,s amiodarone HCl injection will be ...
Cached Medicine News:Health News:IPRO Welcomes Back Anthony Shih as Chief Quality Officer, Strategic Planning Lead 2Health News:Study Disproves Belief That Hepatitis C Blunts HIV Drugs 2Health News:Patient Safety Authority Supports 'National Patient Safety Day' 2Health News:Patient Safety Authority Supports 'National Patient Safety Day' 3Health News:Dataline Announces Participation in Operation Golden Phoenix 2Health News:Dataline Announces Participation in Operation Golden Phoenix 3Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 2Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 3
... Forma 1400 Series ... specifically to revolutionize working ... cabinet. The most comfortable, ... Class II cabinet on ...
... The Premier 12 Holter Analysis Kit incorporates ... Dispersion with other powerful DMS Holter analysis ... TWA analysis possible in less than 10 ... TWA, for visual verification and validation. The ...
... Designed for ease of use and patient ... smooth edges for comfort and is available ... to a perfect fit. For hard to ... trach collar to your specifications. Don't just ...
... more comfortable, and you will too., ... and to avoid the knotty problems associated ... ties, consider the Dale® Tracheostomy Tube Holder. ... narrow fastener tabs of the Dale® Tracheostomy ...
Medicine Products: